Abstract Cellular uptake of clinically important deoxynucleoside analogs is mediated by nucleoside transporters including the human equilibrative nucleoside transporter 1 (hENT1) and the concentrative nucleoside transporter-1 (hCNT1). These transporters are responsible for influx of cytarabine and reduced hENT1 expression is a major resistance mechanism in acute myeloid leukemia. We determined hENT1 and hCNT1 protein expression by immunocytochemistry in 50 diagnostic pediatric acute myeloid leukemia patient samples. All samples expressed hENT1 [9/43 (21%) low; 26/43 (60%) medium and 8/43 (19%) high] and hCNT1 [2/42 (5%) low; 35/42 (83%) medium and 5/42 (12%) high] at the cell membrane and cytoplasm. Statistical analysis showed a non-significant relationship between survival and transporter expression and in vitro drug sensitivity. In conclusion, the nucleoside transporters hENT1 and hCNT1 are broadly expressed in pediatric acute myeloid leukemia at diagnosis.

中文翻译：

---

核苷转运蛋白hENT1（SLC29）和hCNT1（SLC28）在小儿急性髓系白血病中的表达

摘要 临床上重要的脱氧核苷类似物的细胞摄取由核苷转运蛋白介导，包括人类平衡核苷转运蛋白 1 (hENT1) 和浓缩核苷转运蛋白 1 (hCNT1)。这些转运蛋白负责阿糖胞苷的流入，降低的 hENT1 表达是急性髓系白血病的主要耐药机制。我们通过免疫细胞化学在 50 名诊断性小儿急性髓系白血病患者样本中确定了 hENT1 和 hCNT1 蛋白表达。所有样品均表达 hENT1 [9/43 (21%) 低；26/43 (60%) 中等和 8/43 (19%) 高] 和 hCNT1 [2/42 (5%) 低；35/42 (83%) 培养基和 5/42 (12%) 高]在细胞膜和细胞质。统计分析显示存活和转运蛋白表达与体外药物敏感性之间无显着关系。综上所述，